Investing & Markets

Make better decisions with investing tips, technical analysis, market commentary, and more

Personal Finance

Make more, save more, spend smarter, and keep more of what you earn

Business News

Stock market news & analysis


FDA’s Target Date For Aradigm Corporation (ARDM, HEB, DSCO, LLY, BDSI)

By Admin on 07/15/2009 – 6:00 am PDTLeave a Comment

Aradigm Corporation (ARDM) is pending a FDA decision on their drug Liposomal Ciprofloxacin. Lets see if the FDA meets their target date. The FDA has recently misses some important target dates with Hemispherx BioPharma, Inc (Public, AMEX:HEB), Discovery Laboratories, Inc. (NASDAQ:DSCO)‎, Eli Lilly & Co. (NYSE:LLY)‎, and BioDelivery Sciences International, Inc.(Public, NASDAQ:BDSI).

These delays can have huge impacts on the price per share for these companies and make some great opportunities for traders and can make some unhappy longs. Longs now sit back and wait to see what is to come with ARDM.

Let us know what you think about ARDM, their drug Liposomal Ciprofloxacinon, and what you think the FDA will do at our Stock Trading Forums. We are not your normal breed of forums and don’t have the usual bashers, pumpers, and trolls. Stop by today and say hello!

Tags: ARDM, , , , LLY

Related Articles:

  1. Inc. Booted Off Russell Index. Adams Fault? (HEB, CTIC, OCLS, VNDA, TSCM)
  2. Hemispherix Trading Halted? (DNDN, CTIC, PFE, HEB)
  3. Will Hemispherx Biopharma Make The Cut? (HEB)

Comments are closed.